Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allovir Inc (NQ: ALVR )

0.6190 -0.3625 (-36.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allovir Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is Gulfport Energy (GPOR) Stock Down 8% Today?
Gulfport Energy (GPOR) stock is falling on Thursday after the company revealed details of a public share offering from certain investors. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AlloVir Stock Is Diving Thursday
AlloVir Inc (NASDAQ: ALVR) shares are trading lower after the company priced a public offering of common stock. 
Via Benzinga
Why Is AlloVir (ALVR) Stock Down 23% Today?
AlloVir (ALVR) stock is falling hard on Thursday after the company announced the pricing of a $75 million public share offering. 
Via InvestorPlace
Why Root Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 100.8% to $2.65 in pre-market trading after dropping 43% on Wednesday. 
Via Benzinga
Why AlloVir Stock Is Tumbling After Hours
AlloVir Inc (NASDAQ: ALVR) shares are trading lower in Wednesday's after-hours session after the company proposed a public offering. 
Via Benzinga
AlloVir: Q1 Earnings Insights
Via Benzinga
AlloVir, DigitalOcean And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. AlloVir, Inc. (NASDAQ: ALVR) shares dipped 24.1% to $3.74 in pre-market... 
Via Benzinga
AlloVir Announces Pricing of Public Offering of Common Stock
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Proposed Public Offering of Common Stock
From AlloVir, Inc.
Via Business Wire
Why Shares of AlloVir Jumped This Week
The company's lead therapy fared well in preventing infections for kidney transplant patients. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. 
Via Benzinga
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
From AlloVir
Via Business Wire
AlloVir Reports First Quarter 2023 Financial Results
From AlloVir
Via Business Wire
AlloVir to Present at the BofA Securities 2023 Health Care Conference
From AlloVir, Inc.
Via Business Wire
AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections
AlloVir Inc (NASDAQ: ALVR) announced the presentation of long-term, follow-up data from the Phase 2 study of posoleucel to prevent infections from six viruses in allogeneic hematopoietic cell... 
Via Benzinga
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
From AlloVir, Inc.
Via Business Wire
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
From AlloVir
Via Business Wire
AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall
Via Benzinga
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
From AlloVir, Inc.
Via Business Wire
AlloVir to Participate in the SVB Securities Global Biopharma Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
From AlloVir, Inc.
Via Business Wire
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
From AlloVir
Via Business Wire
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
From AlloVir
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.